

Glioma

Recurrent

High Grade

Pre- Avastin

FGFR1-3
Alteration

Surgical
Procedural
Candidates

BRAF
Mutation

IDH
Mutant

BRN0048
[Phase I, First-In-Human Multicenter Open-Label Study of ABM-1310, Administered Orally in Adult Patients with Advanced Solid Tumors](#)
PI: Nagpal
Sponsor: ABM Therapeutics, Inc.

BRN0061
Phase II Multicenter Open Label Two Parts Clinical Study to Evaluate Efficacy & Safety of Safusidenib Erbumine in Isocitrate Dehydrogenase 1 (IDH1) Mutant Glioma
PI: Nagpal
Sponsor: AnHeart Therapeutics Inc.

BRN0056
[Phase I/II Dose-Escalation Study of Candidate GBM Vaccine VBI-1901 with Subsequent Extension of Optimal Dose in Recurrent GBM Subjects](#)
PI: Nagpal
Sponsor: VBI Vaccines Inc.

BRN0054
[Phase II Pemigatinib in Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations](#)
PI: Lim
Sponsor: Incyte Corporation

BRN0057
Open Label Prospective Pilot Study to Evaluate the Safety & Effectiveness of the NaviFUS System in Conjunction w/ a Standard Treatment Regimen of Bevacizumab (BEV) in Recurrent Glioblastoma
PI: Airan
Sponsor: NaviFUS US LLC

BRN0042
Phase II/III Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
PI: Recht
Sponsor: Global Coalition for Adaptive Research

CCT5061
[Phase I Locoregionally \(LR\) Delivered Autologous B7-H3 Chimeric Antigen Receptor T Cells \(B7-H3CART\) in Recurrent Glioblastoma Multiforme \(GBM\)](#)
PI: Thomas
Sponsor: Stanford University
Priority 1

BRN0045
[Phase I/II Exablate Type 2 for BBBD With Microbubble Resonators in Tx of rGBM in Carboplatin Mono Treatment](#)
PI: Nagpal
Sponsor: InSightec, Inc.

BRN0049
[Phase Ib Evaluate Early Immunologic Pharmacodynamic Parameters Following Neoadjuvant Anti-PD-1 \(Nivolumab\), or the Combination of Anti-PD-1 Plus Anti-CTLA-4 \(Nivolumab Plus Ipilimumab\) in Surgically Accessible Glioblastoma](#)
PI: Lim
Sponsor: Dana Farber Cancer Institute
Priority 3

BRN0062
Randomized Surgical Window of Opportunity Study w/ Dose Escalation to Evaluate Whether Oral Fluoxetine Can Induce Cytotoxic Lysosomal Stress & Enhance Temozolomide Efficacy in Clinical Glioma (The FLIR T Trial)
PI: Nagpal
Sponsor: Duke Cancer Institute
Priority 2

VAR0250
Phase I Open-Label Multi-Center Study to Evaluate the Safety Tolerability Dosimetry & Preliminary Activity of [177Lu]Lu-FF58 in Selected Advanced Solid Tumors
PI: Iagaru
Sponsor: Novartis Pharmaceuticals Corporation

KEY

- Pending
- Open for Enrollment
- Observational Study
- Enrollment on Hold
- Optional Path
- Link Trial Posting
- Extension Study
- Immunotherapy